← All trials
NCT04979468
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 23, 2021
- Primary completion
- Apr 1, 2023
- Completion date
- Apr 1, 2024
- First posted
- Jul 28, 2021
- Last posted
- Jul 28, 2021
- Enrollment
- 440
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Istituto Nazionale Malattie Infettive Lazaro SpallanzaniLead sponsor
- Vita-Salute University of Milano. ItalyOverall official - principal investigator
- University of PaviaOverall official - principal investigator
- University of PadovaOverall official - principal investigator
- University of Modena and Reggio EmiliaOverall official - principal investigator
- University of GenoaOverall official - principal investigator
- Government of ItalyOverall official - principal investigator
- A.O. Ospedale Maggiore di LodiOverall official - principal investigator
- Azienda Ospedaliera Universitaria SeneseOverall official - principal investigator
- University of BresciaOverall official - principal investigator
- Ospedale Amedeo di SavoiaOverall official - principal investigator
- Universita' Cattolica del Sacro CuoreOverall official - principal investigator
- University of PalermoOverall official - principal investigator
- University of Roma La SapienzaOverall official - principal investigator
- Societa' Italiana Di Malattie Infettive E TropicaliOverall official - principal investigator
- Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, MilanoOverall official - principal investigator
- University of MilanOverall official - principal investigator
- University of FlorenceOverall official - principal investigator
- University of FerraraOverall official - principal investigator
- Azienda Ospedaliera Universitaria Policlinico di BariOverall official - principal investigator
- Azienda Ospedaliera San Gerardo di MonzaOverall official - principal investigator
- University of Rome Tor VergataOverall official - principal investigator
- University of BresciaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.